Voices
Misty Dawn Shields: ISL1 Neuroendocrine Subtype in SCLC Offers Durable Response to Lurbinectedin
Misty Dawn Shields/X

Misty Dawn Shields: ISL1 Neuroendocrine Subtype in SCLC Offers Durable Response to Lurbinectedin

Misty Dawn Shields, Assistant Professor at Indiana University School of Medicine, shared a post on LinkedIn:

“Never underestimate the power of one.

One patient can change everything. Discovery lies in the outliers.

Ask why. Follow the science.”

Misty Dawn Shields: ISL1 Neuroendocrine Subtype in SCLC Offers Durable Response to Lurbinectedin

Title: ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin

Authors: Misty D. Shields, Katherine G. Minton, Hilal Ozakinci, Tianhao Zhou, Olivia C. Terry, Paresh Kumar, Reem Akel, Luc Girard, John D. Minna, Theresa A. Boyle, John M. Koomen, Michael Shafique

Read the full article.

Misty Dawn Shields: ISL1 Neuroendocrine Subtype in SCLC Offers Durable Response to Lurbinectedin

Other articles featuring Misty Dawn Shields on OncoDaily.

cancer Hilal Ozakinci John D. Minna John M. Koomen Katherine G. Minton Luc Girard Michael Shafique Misty D. Shields Olivia C. Terry OncoDaily Oncology Paresh Kumar Reem Akel small cell lung cancer Theresa A. Boyle Tianhao Zhou